Bipolar hormone therapy shows promise in stubborn prostate cancer
NCT ID NCT04558866
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of two hormone-based drugs—darolutamide and high-dose testosterone—in 51 men with metastatic castration-resistant prostate cancer, a form that no longer responds to standard hormone therapy. The approach, called extreme bipolar androgen therapy, aims to control cancer growth by cycling between blocking and flooding the body with male hormones. The main goal is to see how long the cancer stays under control without spreading.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
darolutamide and testosterone cypionate
What this could lead to
If successful, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is a small, early-phase trial with only 51 participants and no comparison group. The combination may cause side effects or fail to control the cancer long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CTTB - Centro de Tratamento de Tumores Botafogo (Oncoclínicas)
Rio de Janeiro, Rio de Janeiro, 22.250-905, Brazil
-
HIAE - Hospital Israelita Albert Einstein
São Paulo, São Paulo, 05.653-000, Brazil
-
HMV - Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, 90.035-000, Brazil
-
Hospital São Rafael - Oncologia D'Or BA
Salvador, Estado de Bahia, 41.253-190, Brazil
-
Hospital Sírio-Libanês DF
Brasília, Federal District, 70.200-730, Brazil
-
Hospital Sírio-Libanês SP
São Paulo, São Paulo, 01.308-050, Brazil